BioXcel Therapeutics, Inc.
No SEC Form 4 filings for $BTAI in the last 30 days.
See all $BTAI insider activity →Teva (TEVA) agreed to a $125M bid for BioXcel Therapeutics' (BTAI) assets, including Igalmi and BXCL501, with $57.5M upfront and $67.5M in milestones. BioXcel filed for bankruptcy, shares dropped 70%. Teva aims to expand its neuroscience portfolio, following a $700M acquisition in June.
Teva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.
BioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously reported, on August 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) and its subsidiaries (together with the Company, the “Debtors”) each
Over the past 7 days, AlphAI's AI scored 1 news story mentioning BTAI (BioXcel Therapeutics, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent BTAI coverage spans corporate actions, mergers & acquisitions and market movers.
BTAI shares already fell >70%; the bid may set a floor price but limited upside.
Asset sale could provide liquidity to BioXcel’s creditors; shareholders may see limited upside.
The company receives debtor‑in‑possession financing but loses Nasdaq listing, likely pressuring the stock lower.
The deal provides a baseline offer and triggers a bankruptcy auction, likely pressuring BTAI stock lower.
Bankruptcy filing likely depresses stock and may lead to restructuring.
AlphAI scores every news story that mentions BTAI with an AI model for sentiment and relevance, and aggregates insider trades from BioXcel Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Teva (TEVA) agreed to a $125M bid for BioXcel Therapeutics' (BTAI) assets, including Igalmi and BXCL501, with $57.5M upfront and $67.5M in milestones. BioXcel filed for bankruptcy, shares dropped 70%. Teva aims to expand its neuroscience portfolio, following a $700M acquisition in June.
3 min readTeva Pharmaceuticals (TEVA) agreed to a stalking-horse bid of up to $125M for BioXcel Therapeutics' (BTAI) assets, including $57.5M in cash and up to $67.5M in contingent payments. The deal, subject to court approval, includes IGALMI and other assets. The FDA has a 2026 target date for a supplemental application to expand IGALMI's label to at-home use. Competing bids may arise.
3 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously reported, on August 27, 2026, BioXcel Therapeutics, Inc. (the “Company”) and its subsidiaries (together with the Company, the “Debtors”) each
2 min readBioXcel Therapeutics (BTAI) sold its assets to Teva Pharmaceuticals in a court-supervised auction. The deal includes IGALMI and BXCL501, with a PDUFA date of November 14, 2026. BioXcel filed for Chapter 11 bankruptcy. BTAI stock fell 74.76% Friday, trading at $0.18.
2 min readCarets Corp is exploring a potential sale, including its technology and patents. Algorhythm Holdings (RIME) and Biomerica (BMRA) are evaluating strategic alternatives. nVent Electric (NVT) acquired Maverick Power for $1.75B, with up to $550M more in performance-based payments. Descartes (DSGX) bought Tai for $100M, and Navitas (NVTS) acquired Claros for up to $232.8M. Booz Allen (BAH) completed a $720M acquisition, and Elastic (ESTC) acquired Deductive AI. BioXcel (BTAI) filed for Chapter 11 ban
3 min readU.S. stocks were mixed on Friday, with the Dow up 0.19% and the NASDAQ down 0.01%. The Chicago PMI fell to 47.1 in August, missing estimates. Quoin Pharmaceuticals (QNRX) rose 43% after positive clinical trial results and financing news. BioXcel Therapeutics (BTAI) dropped 73% after filing for bankruptcy.
2 min readBioXcel Therapeutics (BTAI) agreed to sell its assets to Teva Pharmaceuticals and filed for Chapter 11 bankruptcy. The deal includes IGALMI and BXCL501. The company secured $19M in financing and plans to seek higher bids. IGALMI remains available, and BXCL501's FDA decision is due November 14. BTAI stock is down 46.30% pre-market.
2 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. The information set forth below in Item 1.03 of this Current Report on Form 8-K is incorporated herein by reference. Item 1.03 Bankruptcy or Receivership. On August 27, 2026 (the “Petition Date”), BioXcel Therapeutics, Inc. (t
2 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 24, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Fourteenth Amendment to Credit Agreement and Guaranty (the “Fourteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 1
1 min readBioXcel Therapeutics, Inc. (BTAI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On August 21, 2026, BioXcel Therapeutics, Inc. (the “Company”) entered into the Thirteenth Amendment to Credit Agreement and Guaranty (the “Thirteenth Amendment”), which amended the Credit Agreement and Guaranty, dated April 1
1 min read
